Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | ATG7 | O95352 | 1/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737331 | 1.00 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ADORA2BATG7 | |
| SCHEMBL13598822 | 0.86 | ADORA2A (0.50) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL14075956 | 0.86 | ADORA2A (0.50) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL13598784 | 0.86 | ADORA2A (0.50) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL4423328 | 0.86 | ADORA2A (0.50) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL14089315 | 0.85 | ADORA3 (0.50) | ADORA2AADORA3ADORA1ADORA2BPRMT5 | |
| SCHEMBL4426285 | 0.85 | ADORA3 (0.50) | ADORA2AADORA3ADORA1ADORA2BPRMT5 | |
| SCHEMBL13598668 | 0.85 | ADORA3 (0.50) | ADORA2AADORA3ADORA1ADORA2BPRMT5 | |
| SCHEMBL13598823 | 0.85 | ADORA3 (0.50) | ADORA2AADORA3ADORA1ADORA2BPRMT5 | |
| SCHEMBL14089579 | 0.83 | ADORA3 (0.50) | ADORA2AADORA3ADORA1ADORA2BPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | IONIS PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885ADORA3 334/4885ADORA1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.